دورية أكاديمية
أعرض في EDS

Selenium Nanoparticles Modulate Steroidogenesis-Related Genes and Improve Ovarian Functions via Regulating Androgen Receptors Expression in Polycystic Ovary Syndrome Rat Model.

التفاصيل البيبلوغرافية
العنوان: Selenium Nanoparticles Modulate Steroidogenesis-Related Genes and Improve Ovarian Functions via Regulating Androgen Receptors Expression in Polycystic Ovary Syndrome Rat Model.
المؤلفون: Abdallah ABE; Department of Physiology, Faculty of Medicine, Zagazig University, Zagazig, Egypt., El-Ghannam MA; Department of Physiology, Faculty of Medicine, Zagazig University, Zagazig, Egypt., Hasan AA; Department of Pharmaceutics, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt., Mohammad LG; Department of Physiology, Faculty of Medicine, Zagazig University, Zagazig, Egypt., Mesalam NM; Biological Applications Department, Nuclear Research Center, Egyptian Atomic Energy Authority, 13759, Cairo, Egypt. mesalam.noura@gmail.com., Alsayed RM; Department of Physiology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
المصدر: Biological trace element research [Biol Trace Elem Res] 2023 Dec; Vol. 201 (12), pp. 5721-5733. Date of Electronic Publication: 2023 Mar 16.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Humana Press Country of Publication: United States NLM ID: 7911509 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1559-0720 (Electronic) Linking ISSN: 01634984 NLM ISO Abbreviation: Biol Trace Elem Res Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London, Clifton, N. J.] Humana Press.
مواضيع طبية MeSH: Polycystic Ovary Syndrome*/chemically induced , Polycystic Ovary Syndrome*/drug therapy , Polycystic Ovary Syndrome*/genetics , Selenium*/pharmacology , Selenium*/therapeutic use , Insulin Resistance*, Humans ; Rats ; Female ; Animals ; Androgens/pharmacology ; Androgens/therapeutic use ; Receptors, Androgen/genetics ; Receptors, Androgen/therapeutic use ; RNA, Messenger
مستخلص: Polycystic ovary syndrome (PCOS) occurs during the reproductive period in women and is characterized by reproductive, endocrine, and metabolic disorders. Androgen plays a decisive role in its pathogenesis due to the interaction between hyperandrogenism and insulin resistance, which might be improved by selenium nanoparticles (SeNPs). The present study aimed to clarify the effect of SeNPs on androgen synthesis and action in the PCOS model and the resulting effect on ovarian function. Fifty-five 7-week-old female albino rats (90-105 g) were divided equally into five groups: control (C), fed a standard diet for 11 weeks; high-fat diet (HFD) group, fed HFD for 11 weeks; HFD and letrozole (L) (HFD + L), fed HFD for 11 weeks and administrated orally with L, at a daily dose of 1 mg/kg BW, for three weeks from the 7th to 9th week of the trial; HFD + L + 0.1SeNPs and HFD + L + 0.2SeNPs groups, treated the same as HFD + L group and orally gavaged SeNPs at daily doses of 0.1 and 0.2 mg/kg BW, respectively, during the last 14 day of the experiment. Daily determination of estrous cycle was performed, and at the end of the experimental period, BMI, serum glucose, insulin, HOMA-IR, lipid profile, sex hormones, TNF-α, IL6, oxidative stress biomarkers, ovarian mRNA expression of different proteins and enzymes involved in steroidogenesis, pathological examination, and immunohistochemical staining for androgen receptor (AR) were evaluated. Treatment of SeNPs restored estrous cyclicity, decreased BMI, and insulin resistance, improved dyslipidemia, reduced serum testosterone, and improved ovarian histopathology in PCOS rats. Furthermore, the anti-inflammatory and antioxidant impacts of SeNPs were remarkably noticed. Administration of SeNPs decreased androgen synthesis and expression of ovarian AR protein by decreasing the mRNA expression of STAR, Cyp11A1, Cyp17A1, and HSD17B3 and increasing the expression of Cyp19α1. Conclusively, SeNPs decreased androgen synthesis and blocked the vicious circle initiated by excessive androgen secretion via decreased AR expression. Thus, it may effectively treat PCOS cases by eliminating its reproductive, endocrine, and metabolic dysfunctions.
(© 2023. The Author(s).)
References: Adv Colloid Interface Sci. 2022 Oct;308:102772. (PMID: 36087561)
Diabet Med. 1992 Jul;9(6):503-12. (PMID: 1643797)
Circulation. 2001 Mar 13;103(10):1410-5. (PMID: 11245645)
Front Endocrinol (Lausanne). 2022 Mar 28;13:838204. (PMID: 35418943)
Eur J Endocrinol. 1998 Oct;139(4):461-7. (PMID: 9820626)
Gynecol Endocrinol. 2021 May;37(5):456-461. (PMID: 32960117)
PLoS One. 2019 Aug 23;14(8):e0220779. (PMID: 31442295)
J Steroid Biochem Mol Biol. 2015 Jan;145:213-25. (PMID: 25008465)
Clin Obstet Gynecol. 2021 Mar 1;64(1):3-11. (PMID: 32701517)
Biofactors. 2001;15(1):27-38. (PMID: 11673642)
Mol Cell Endocrinol. 2000 Jan 25;159(1-2):25-35. (PMID: 10687849)
Iran J Basic Med Sci. 2018 Jun;21(6):645-650. (PMID: 29942457)
Fertil Steril. 2005 Jul;84(1):82-7. (PMID: 16009161)
Hum Mol Genet. 1997 Mar;6(3):397-402. (PMID: 9147642)
Clin Chim Acta. 1995 May 15;236(2):173-80. (PMID: 7554284)
Hepatology. 1998 Sep;28(3):689-94. (PMID: 9731560)
Cell J. 2017 Oct;19(3):452-460. (PMID: 28836407)
Rev Assoc Med Bras (1992). 2014 Jul;60(4):349-56. (PMID: 25211419)
J Ethnopharmacol. 2022 Jun 12;291:115161. (PMID: 35271948)
Steroids. 2002 Mar;67(3-4):277-89. (PMID: 11856552)
J Nutr Biochem. 2012 Oct;23(10):1238-44. (PMID: 22209003)
Nat Rev Endocrinol. 2018 May;14(5):270-284. (PMID: 29569621)
Endokrynol Pol. 2011;62(2):120-8. (PMID: 21528473)
Biol Trace Elem Res. 2022 Feb;200(2):768-779. (PMID: 33674946)
Arch Med Res. 2004 Mar-Apr;35(2):103-8. (PMID: 15010188)
Int J Mol Sci. 2019 Jun 03;20(11):. (PMID: 31163591)
Gynecol Endocrinol. 2013 May;29(5):478-82. (PMID: 23461365)
Endocrinology. 2014 Aug;155(8):3146-59. (PMID: 24877633)
Am J Med. 2012 Mar;125(3):302.e1-7. (PMID: 22340932)
Cell Metab. 2007 Oct;6(4):307-19. (PMID: 17908559)
Gynecol Obstet Invest. 2013;76(4):209-13. (PMID: 24157654)
Int J Nanomedicine. 2015 Oct 29;10:6741-56. (PMID: 26604749)
J Clin Endocrinol Metab. 1979 Oct;49(4):514-9. (PMID: 479344)
Saudi J Biol Sci. 2022 Feb;29(2):1197-1209. (PMID: 35197787)
J Mol Endocrinol. 2005 Oct;35(2):305-16. (PMID: 16216911)
Chin Med. 2021 Apr 29;16(1):36. (PMID: 33926485)
Trends Endocrinol Metab. 2007 Sep;18(7):280-5. (PMID: 17692530)
Biol Reprod. 2013 Oct 17;89(4):91. (PMID: 23966322)
Trends Endocrinol Metab. 2017 Mar;28(3):186-198. (PMID: 27988256)
Arch Med Res. 2006 Oct;37(7):830-9. (PMID: 16971221)
Andrologia. 2013 Dec;45(6):379-85. (PMID: 23013062)
Front Pharmacol. 2018 Nov 19;9:1325. (PMID: 30524282)
J Clin Invest. 1998 Jun 15;101(12):2615-21. (PMID: 9637694)
J Clin Biochem Nutr. 2011 Jan;48(1):40-5. (PMID: 21297910)
Endocrinology. 2007 Aug;148(8):3781-91. (PMID: 17495003)
Braz J Biol. 2002 Nov;62(4A):609-14. (PMID: 12659010)
Molecules. 2016 Nov 19;21(11):. (PMID: 27869771)
Biomed Pharmacother. 2022 May;149:112870. (PMID: 35367769)
Molecules. 2022 Sep 01;27(17):. (PMID: 36080407)
Endocr J. 2017 Jan 30;64(1):7-14. (PMID: 27665725)
Biol Reprod. 2008 Mar;78(3):380-9. (PMID: 18003945)
N Engl J Med. 1992 Jul 16;327(3):157-62. (PMID: 1319000)
Reproduction. 2015 Oct;150(4):289-96. (PMID: 26199450)
J Therm Biol. 2022 Feb;104:103195. (PMID: 35180972)
BMC Complement Med Ther. 2021 Nov 29;21(1):291. (PMID: 34844580)
Hippokratia. 2009 Oct;13(4):216-23. (PMID: 20011085)
Anat Cell Biol. 2019 Dec;52(4):511-517. (PMID: 31949991)
Heliyon. 2020 May 30;6(5):e04045. (PMID: 32509990)
Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
Lipids Health Dis. 2018 Jul 21;17(1):165. (PMID: 30031400)
J Biol Chem. 1990 Jan 15;265(2):1124-8. (PMID: 2153102)
Endocr Rev. 1988 Aug;9(3):295-318. (PMID: 3061784)
Fertil Steril. 2014 Jun;101(6):1732-9.e1-2. (PMID: 24666752)
J Ovarian Res. 2015 Mar 22;8:11. (PMID: 25881575)
Reprod Domest Anim. 2009 Oct;44(5):805-14. (PMID: 18992127)
Best Pract Res Clin Endocrinol Metab. 2002 Jun;16(2):263-72. (PMID: 12064892)
Andrology. 2019 Jan;7(1):110-123. (PMID: 30515996)
فهرسة مساهمة: Keywords: Androgen receptors; Ovarian histopathology and immunohistochemistry; PCOS; Selenium nanoparticles; Steroidogenesis; mRNA expression
المشرفين على المادة: 0 (Androgens)
0 (Receptors, Androgen)
H6241UJ22B (Selenium)
0 (RNA, Messenger)
تواريخ الأحداث: Date Created: 20230316 Date Completed: 20231102 Latest Revision: 20231104
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC10620277
DOI: 10.1007/s12011-023-03616-0
PMID: 36922476
قاعدة البيانات: MEDLINE
الوصف
تدمد:1559-0720
DOI:10.1007/s12011-023-03616-0